Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice
Vincent C. Auyeung, Tavienne L. Steinberg, Alina Olivier, Luka Suzuki, Mary E. Moreno, Imran S. Khan, Michael S. Downey, Maike Thamsen, Lu Guo, Dustin J. Maly, Bradley J. Backes, Dean Sheppard, Feroz R. Papa
Vincent C. Auyeung, Tavienne L. Steinberg, Alina Olivier, Luka Suzuki, Mary E. Moreno, Imran S. Khan, Michael S. Downey, Maike Thamsen, Lu Guo, Dustin J. Maly, Bradley J. Backes, Dean Sheppard, Feroz R. Papa
View: Text | PDF
Research Article Pulmonology

Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice

  • Text
  • PDF
Abstract

Stress-induced epithelial plasticity is central to lung regeneration, fibrosis, and malignancy, but how cellular stress leads to differentiation is incompletely understood. Here, we found a central role for IRE1α, a conserved mediator of the unfolded protein response (UPR), in stimulating the plasticity of alveolar type 2 (AT2) cells. In single-cell RNA-seq, IRE1α activity was associated with loss of AT2 identity and progression toward a damage-associated transitional state unique to fibrosis. AT2 plasticity required destructive regulated IRE1α-dependent decay (RIDD), which we demonstrated by deploying PAIR2, a kinase modulator that inhibits RIDD while preserving IRE1α’s adaptive XBP1 mRNA splicing activity. In vivo, selective inhibition of RIDD with PAIR2 reduced AT2 differentiation into profibrotic transitional cells and protected mice from bleomycin-induced pulmonary fibrosis. Mechanistically, we identified the Fgfr2 mRNA as a direct and regulated substrate for IRE1α’s RNase in primary AT2 cells and in a biochemically reconstituted cell-free system. Loss of Fgf signaling caused AT2 differentiation, while gain of signaling protected cells from IRE1α-induced differentiation. We propose that IRE1α downregulates Fgf signaling through RIDD, provoking loss of AT2 identity and differentiation towards a profibrotic phenotype. Thus, IRE1α’s RIDD activity emerges as a novel target for treatment of pulmonary fibrosis and potentially other diseases driven by aberrant epithelial cell plasticity.

Authors

Vincent C. Auyeung, Tavienne L. Steinberg, Alina Olivier, Luka Suzuki, Mary E. Moreno, Imran S. Khan, Michael S. Downey, Maike Thamsen, Lu Guo, Dustin J. Maly, Bradley J. Backes, Dean Sheppard, Feroz R. Papa

×

Figure 5

Fgfr2 is a bona fide substrate for RIDD.

Options: View larger image (or click on image) Download as PowerPoint

Fgfr2 is a bona fide substrate for RIDD.
(A) Dot plot of RIDD candidate...
(A) Dot plot of RIDD candidate genes in cells in the AT2 cluster. Genes were filtered for those that are downregulated after bleomycin injury and whose expression is rescued by IRE1α genetic or pharmacologic loss-of-function. (B) Whole-lung expression of the epithelial Fgfr2 splice isoform (Fgfr2b) after bleomycin exposure and treatment with PAIR2. (C) In vitro cleavage of a T7-transcribed Fgfr2 RNA substrate by IRE1α* with or without the selective IRE1α RNase inhibitor STF083010. (D) In vitro cleavage of Fgfr2 as in C after modulating the kinase domain using the complete inhibitor KIRA8, RIDD-selective inhibitor PAIR2, and complete dephosphorylation (dp) by lambda phage phosphatase. (E) Fgfr2 expression in serum-free, feeder free AT2 organoids after stimulation with the ER stress agent thapsigargin (Tg). Values plotted on a logarithmic scale. (F) Surface Fgfr2 expression by flow cytometry in AT2 organoids, with quantification of mean fluorescence intensity (MFI). Xbp1 splicing (G), Bloc1s1 (H) and Fgfr2 (I) expression in serum-free, feeder free AT2 organoids after stimulation with the ER stress agent thapsigargin (Tg) and treatment with KIRA8 or PAIR2. Values plotted on a logarithmic scale for H and I. (J) Bloc1s1 and Fgfr2 expression in response to dose-titration of G1749 and reversal with the selective IRE1α RNase inhibitor STF083010. Mean ±SEM shown for visual clarity with n = 7 for 0 μM and n = 4 for all other doses, plotted on a logarithmic scale. For all other panels, individual mouse or culture well replicates shown with mean ±SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 by 1-sided Student’s t test with adjusted P values where indicated to correct for multiple hypotheses using Šidák’s method.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts